Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2014; 20(30): 10338-10347
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10338
Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance
Javier Molina-Infante, Javier P Gisbert
Javier Molina-Infante, Department of Gastroenterology, Hospital San Pedro de Alcantara, 10003 Caceres, Spain
Javier P Gisbert, Department of Gastroenterology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28006 Madrid, Spain
Author contributions: Molina-Infante J and Gisbert JP contributed equally to this work.
Correspondence to: Javier Molina-Infante, MD, Department of Gastroenterology, Hospital San Pedro de Alcantara, C/ Pablo Naranjo s/n, 10003 Caceres, Spain. xavi_molina@hotmail.com
Telephone: +34-927-621543 Fax: +34-927-621543
Received: August 25, 2013
Revised: March 14, 2014
Accepted: April 5, 2014
Published online: August 14, 2014
Abstract

The efficacy of triple therapy for Helicobacter pylori infection has dramatically declined over the last decade, largely related to increasing clarithromycin resistance rates. From a microbiological standpoint, bismuth quadruple therapy is the ideal replacement since it combines drugs for which resistance does not impair its efficacy. Nonetheless, several obstacles such as availability, complexity or tolerance prevent a general implementation of bismuth quadruple therapy, so non-bismuth quadruple regimens remain the best first-line treatment in clinical practice in many geographical areas. We review the rationale and efficacy of several optimization tools (increasing the length of duration, high-dose acid suppression, probiotics), which have been largely evaluated over the last 5 years to increase the effectiveness of standard triple therapy. Then, we update available evidence on the effectiveness of several non-bismuth quadruple therapies (sequential, concomitant, hybrid, miscellaneous therapy), which have gained interest lately. We also revise evidence on the efficacy of the aforementioned optimization tools for non-bismuth quadruples schemes and, finally we provide a novel regionalized therapeutic algorithm, based on novel formulas recently developed for predicting the outcome of non-bismuth quadruple regimens, upon local antibiotic resistance rates.

Keywords: Helicobacter pylori, Eradication, Clarithromycin, Sequential, Concomitant, Hybrid, Antibiotic resistance, Bismuth

Core tip: Triple therapy is no longer effective to eradicate Helicobacter pylori infection in most settings across the world. Bismuth quadruple therapy has resurfaced as an ideal replacement, despite its implementation in clinical practice may be troublesome. As such, non-bismuth quadruple therapies remain in the therapeutic front line in clinical practice. This article updates available evidence over the last five years on the efficacy of several non-bismuth quadruple schemes and different tools used to optimize them, providing a novel regionalized therapeutic algorithm, according to novel predicting models based on local antibiotic resistance rates.